Exanta “Not Approvable” Decision Leads To $80 mil. Charge
AstraZeneca has taken an $80 mil. charge against half the assets associated with Exanta following FDA's "not approvable" decision
AstraZeneca has taken an $80 mil. charge against half the assets associated with Exanta following FDA's "not approvable" decision